164 related articles for article (PubMed ID: 20017657)
21. Drug development. A European-inspired renaissance for China's drug industry?
Xin H
Science; 2007 Jul; 317(5837):436-7. PubMed ID: 17656689
[No Abstract] [Full Text] [Related]
22. [Current challenges for the pharmaceutical research industry].
Chalchat B
Ann Pharm Fr; 1993; 51(1):16-25. PubMed ID: 8215118
[TBL] [Abstract][Full Text] [Related]
23. Marketing decision support systems for strategy building.
Rao SK
Mark Health Serv; 2000; 20(2):14-8. PubMed ID: 11183424
[TBL] [Abstract][Full Text] [Related]
24. Boston means business for drug companies.
Mervis J
Science; 2005 Jul; 309(5735):723. PubMed ID: 16051782
[No Abstract] [Full Text] [Related]
25. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
Ross ME; Nydick RL
J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
[TBL] [Abstract][Full Text] [Related]
26. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions.
Matter A; Keller TH
Drug Discov Today; 2008 Apr; 13(7-8):347-52. PubMed ID: 18405848
[TBL] [Abstract][Full Text] [Related]
27. [Exclusivity of data in drug registration files and Israel's international status with regard to intellectual property rights protection].
Lipschitz Y; Tamir O; Shemer J
Harefuah; 2004 Dec; 143(12):845-8, 912. PubMed ID: 15666700
[TBL] [Abstract][Full Text] [Related]
28. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
29. Biopharma business models in Canada.
March-Chordà I; Yagüe-Perales RM
Drug Discov Today; 2011 Aug; 16(15-16):654-8. PubMed ID: 21708279
[TBL] [Abstract][Full Text] [Related]
30. Strategic considerations for the biotechnology business to the year 2000.
Cometta S
Arzneimittelforschung; 1989 Aug; 39(8):929-34. PubMed ID: 2818683
[TBL] [Abstract][Full Text] [Related]
31. Issues and concerns in nanotech product development and its commercialization.
Kaur IP; Kakkar V; Deol PK; Yadav M; Singh M; Sharma I
J Control Release; 2014 Nov; 193():51-62. PubMed ID: 24933600
[TBL] [Abstract][Full Text] [Related]
32. Patentees research and development expenditure in Canada.
Li S; Tomalin A
J Pharm Pharm Sci; 2002; 5(1):5-11. PubMed ID: 12042113
[TBL] [Abstract][Full Text] [Related]
33. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
34. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.
Houston JG; Banks MN; Binnie A; Brenner S; O'Connell J; Petrillo EW
Drug Discov Today; 2008 Jan; 13(1-2):44-51. PubMed ID: 18190863
[TBL] [Abstract][Full Text] [Related]
35. Product-related research: how research can contribute to successful life-cycle management.
Sandner P; Ziegelbauer K
Drug Discov Today; 2008 May; 13(9-10):457-63. PubMed ID: 18468564
[TBL] [Abstract][Full Text] [Related]
36. [The drug industry and research: status in Germany].
Geursen R
Zentralbl Chir; 1996; 121(7):603-5. PubMed ID: 8967203
[TBL] [Abstract][Full Text] [Related]
37. How pharmaceutical industry funding affects trial outcomes: causal structures and responses.
Sismondo S
Soc Sci Med; 2008 May; 66(9):1909-14. PubMed ID: 18299169
[TBL] [Abstract][Full Text] [Related]
38. Predators and prey: a new ecology of competition.
Moore JF
Harv Bus Rev; 1993; 71(3):75-86. PubMed ID: 10126156
[TBL] [Abstract][Full Text] [Related]
39. IP litigation in China could drive innovation.
Jia H
Nat Biotechnol; 2004 Apr; 22(4):368. PubMed ID: 15060539
[No Abstract] [Full Text] [Related]
40. A call for sharing: adapting pharmaceutical research to new realities.
Munos BH; Chin WW
Sci Transl Med; 2009 Dec; 1(9):9cm8. PubMed ID: 20368187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
